Reactive oxygen species generation is essential for cisplatin-induced accelerated senescence in hepatocellular carcinoma

Abstract

Accelerated senescence is important because this process is involved in tumor suppression and has been induced by many chemotherapeutic agents. The platinum-based chemotherapeutic agent cisplatin displays a wide range of antitumor activities. However, the molecular mechanism of cisplatin-induced accelerated senescence in hepatocellular carcinoma (HCC) remains unclear. In the present study, the growth inhibitory effect of cisplatin on HepG2 and SMMC-7721 cells was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cellular senescence was then assessed by β-galactosidase assay. Senescence-related factors, including p53, p21, and p16, were evaluated by quantitative reverse transcription-polymerase chain reaction. Reactive oxygen species (ROS) was analyzed by flow cytometry. Our results revealed that cisplatin reduced the proliferation of HepG2 and SMMC-7721 cells in a dose- and time-dependent manner. Senescent phenotype observed in cisplatin-treated hepatoma cells was dependent on p53 and p21 activation but not on p16 activation. Furthermore, cisplatin-induced accelerated senescence depended on intracellular ROS generation. The ROS scavenger N-acetyl-L-cysteine also significantly suppressed the cisplatin-induced senescence of HepG2 and SMMC-7721 cells. In conclusion, our results revealed a functional link between intracellular ROS generation and cisplatin-induced accelerated senescence, and this link may be used as a potential target of HCC.

Keywords

reactive oxygen species / senescence / cisplatin / hepatocellular carcinoma

References

[1] HayflickL. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res1965; 37(3): 614-636

[2] DimriGP, LeeX, BasileG, AcostaM, ScottG, RoskelleyC, MedranoEE, LinskensM, RubeljI, Pereira-SmithO. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA1995; 92(20): 9363-9367

[3] ChangBD, BroudeEV, DokmanovicM, ZhuH, RuthA, XuanY, KandelES, LauschE, ChristovK, RoninsonIB. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res1999; 59(15): 3761-3767

[4] te PoeleRH, OkorokovAL, JardineL, CummingsJ, JoelSP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res2002; 62(6): 1876-1883

[5] FangK, ChiuCC, LiCH, ChangYT, HwangHT. Cisplatin-induced senescence and growth inhibition in human non-small cell lung cancer cells with ectopic transfer of p16INK4a. Oncol Res2007; 16(10): 479-488

[6] WangX, WongSC, PanJ, TsaoSW, FungKH, KwongDL, ShamJS, NichollsJM. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res1998; 58(22): 5019-5022

[7] PanieriE, GogvadzeV, NorbergE, VenkateshR, OrreniusS, ZhivotovskyB. Reactive oxygen species generated in different compartments induce cell death, survival, or senescence. Free Radic Biol Med2013; 57: 176-187

[8] LiSK, SmithDK, LeungWY, CheungAM, LamEW, DimriGP, YaoKM. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J Biol Chem2008; 283(24): 16545-16553

[9] QuK, XuX, LiuC, WuQ, WeiJ, MengF, ZhouL, WangZ, LeiL, LiuP. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma. Cancer Lett2013; 331(1): 105-114

[10] RobersonRS, KussickSJ, VallieresE, ChenSY, WuDY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res2005; 65(7): 2795-2803

[11] ColavittiR, FinkelT. Reactive oxygen species as mediators of cellular senescence. IUBMB Life2005; 57(4-5): 277-281

[12] IshikawaF. Cellular senescence, an unpopular yet trustworthy tumor suppressor mechanism. Cancer Sci2003; 94(11): 944-947

[13] ColladoM, GilJ, EfeyanA, GuerraC, SchuhmacherAJ, BarradasM, BenguríaA, ZaballosA, FloresJM, BarbacidM, BeachD, SerranoM. Tumour biology: senescence in premalignant tumours. Nature2005; 436(7051): 642

[14] ColladoM, SerranoM. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer2010; 10(1): 51-57

[15] XueW, ZenderL, MiethingC, DickinsRA, HernandoE, KrizhanovskyV, Cordon-CardoC, LoweSW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature2007; 445(7128): 656-660

[16] JonesKR, ElmoreLW, Jackson-CookC, DemastersG, PovirkLF, HoltSE, GewirtzDA. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol2005; 81(6): 445-458

[17] SantarosaM, Del ColL, ToninE, CaragnanoA, VielA, MaestroR. Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. Mol Cancer Ther2009; 8(4): 844-854

[18] OzturkN, ErdalE, MumcuogluM, AkcaliKC, YalcinO, SenturkS, Arslan-ErgulA, GurB, YulugI, Cetin-AtalayR, YakicierC, YagciT, TezM, OzturkM. Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. Proc Natl Acad Sci USA2006; 103(7): 2178-2183

[19] PetrosWP, BroadwaterG, BerryD, JonesRB, VredenburghJJ, GilbertCJ, GibbsJP, ColvinOM, PetersWP. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res2002; 8(3): 698-705

[20] SchmittCA, FridmanJS, YangM, LeeS, BaranovE, HoffmanRM, LoweSW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell2002; 109(3): 335-346

[21] ChangBD, XuanY, BroudeEV, ZhuH, SchottB, FangJ, RoninsonIB. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene1999; 18(34): 4808-4818

[22] ChenZ, TrotmanLC, ShafferD, LinHK, DotanZA, NikiM, KoutcherJA, ScherHI, LudwigT, GeraldW, Cordon-CardoC, PandolfiPP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature2005; 436(7051): 725-730

[23] RayessH, WangMB, SrivatsanES. Cellular senescence and tumor suppressor gene p16. Int J Cancer2012; 130(8): 1715-1725

[24] SteinGH, DrullingerLF, SoulardA, DulićV. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol1999; 19(3): 2109-2117

[25] VigneronA, VousdenKH. p53, ROS and senescence in the control of aging. Aging (Albany NY)2010; 2(8): 471-474

[26] LimSC, ChoiJE, KangHS, HanSI. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer2010; 126(7): 1582-1595

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag Berlin Heidelberg